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Objectives. To assess the safety and efficacy of pre-emptive treatment of optical coherence tomography- (OCT-) derived vul-
nerable, non-flow-limiting, non-culprit lesions in patients with myocardial infarction (MI). Background. Intracoronary imaging
with OCT can aid in the decision to treat non-flow-limiting lesions by identifying vulnerable plaques. Pre-emptive treatment of
these lesions might improve patient outcome by “sealing” these plaques. Bioresorbable vascular scaffolds (BVS) have theoretical
benefit for this treatment because they dissolve completely over time.Methods. In patients presenting withMI, non-culprit lesions
with a fractional flow reserve ≥0.8 were imaged with OCT. Vulnerable plaques were randomised to either percutaneous coronary
intervention (PCI) with bioresorbable vascular scaffold (BVS) placement or optimal medicinal therapy (OMT). "e primary
outcome was a composite of all-cause mortality, non-fatal MI, and unplanned revascularisation at 1-year follow-up. Results. "e
trial was stopped prematurely after retraction from the market of the Absorb BVS. At that time, a total of 34 patients were
randomised. At two years, the composite endpoint occurred 3 times (18.8%) in the BVS group and 1 time (6.3%) in the OMT
group. Apart from one elective PCI for stable angina in the OMT group, no target lesions in any group were revascularised.
Conclusions. Pre-emptive stenting of vulnerable plaques had no evident benefit compared to conservative treatment. However,
due to the low number of included patients, no definite conclusions could be drawn. Identifying and potentially treating
vulnerable plaques remains an important target for future research."is trial is registered under https://www.trialregister.nl/trial/
NL4177 on 08-12-2015.
1. Introduction
Although percutaneous coronary intervention and phar-
macologic therapies have improved the prognosis for pa-
tients with acute coronary syndrome (ACS), recurrent major
adverse cardiac events (MACE) are still common. Such
events may occur at the original culprit lesion site, at pre-
existing non-culprit lesions or at newly developed lesions.
For non-culprit lesions, intracoronary physiology can guide
in the decision to perform stent placement. However, the
MACE rate in ACS patients after FFR-guided deferral of
stent placement in these non-culprit lesions is high as
compared to stable coronary artery disease (CAD) [1].
It has been advocated that anatomic plaque character-
ization using intracoronary imaging could further aid the
treatment decision for non-culprit lesions in ACS. Several
pathology studies have shown that there are certain mor-
phological plaque characteristics that make an atheroscle-
rotic plaque vulnerable to rupture and subsequent
myocardial infarction (MI). "ese lesions generally have a
large necrotic core and a thin overlying fibrous cap and are
frequently referred to as thin-cap fibroatheromas (TCFA)
[2]. "ese features have also been prospectively identified in
vivo. In the PROSPECT study, a cohort of ACS patients
underwent three-vessel intravascular ultrasound (IVUS) for
the assessment of plaque morphology during the index
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invasive coronary angiography [3]. After a median follow-up
of 3.4 years, it was shown that non-culprit lesions identified
as TCFA had a hazard ratio of 3.35 for causing futureMACE.
Nevertheless, the use of IVUS for assessing plaque com-
ponents is hampered by its relatively limited spatial reso-
lution. In pathology studies, the average fibrous cap
thickness of ruptured plaques at autopsy was 23 μm, and
95% of all ruptured caps measured less than 65 μm [4],
whereas IVUS only has a spatial resolution of 100 μm. Since
PROSPECT, Optical Coherence Tomography (OCT)
intracoronary imaging has become available. OCT has a
much higher spatial resolution of approximately 10 μm,
which truly allows for measurement of fibrous cap thickness.
Additionally, OCT is able to identify infiltrating macro-
phages, which is another hallmark of unstable lesions [5].
"is intravascular imaging technique, therefore, seems to be
more suitable for the evaluation of plaque morphology [6].
Identifying vulnerable plaques in vivo has led to the
hypothesis of preventive intervention of these lesions. A
small study has shown that stenting TCFA resulted in the
development of neointima, thereby “sealing” the vulnerable
plaque [7]. A bioresorbable vascular scaffold (BVS) might
have a theoretical benefit for this treatment because it
dissolves completely over time. "erefore, we initiated the
PECTUS trial, a multicenter randomised controlled trial
comparing PCI with BVS (Absorb) placement versus Op-
timal Medicinal "erapy (OMT) of OCT-determined vul-
nerable, FFR-negative, non-culprit lesions in patients with
myocardial infarction (NL4177).
"e trial was stopped prematurely after the reporting of
increased stent-thrombosis and the subsequent retraction
from the market of the Absorb stent [8, 9]. At that time, a
total of 34 out of the 500 planned patients were enrolled in
the trial. Here, we report the OCT characteristics and the
clinical outcomes of these 34 patients.
2. Materials and Methods
2.1. Study Flow. A flowchart of the study design is shown in
Figure 1. Patients presenting to the hospital with a myo-
cardial infarction (ST-elevation or a non-ST-elevation) were
screened for potential inclusion in the study. Patients were
treated according to the current guidelines for the man-
agement of ACS, including referral for invasive coronary
angiography (ICA) and (potential) PCI of the culprit artery.
Patients were subsequently approached for participation in
the study if any intermediate non-culprit stenoses were
identified during ICA and if they were eligible for inclusion
based on the criteria listed in Table 1.
After obtaining informed consent, patients underwent a
re-ICA during which the non-culprit lesions were evaluated
for physiological significance by fractional flow reserve
(FFR). FFR-positive (<0.80) lesions were treated with PCI
according to current guidelines. All non-flow-limiting
(FFR≥ 0.80) lesions were imaged with OCT. OCT Images
were acquired using a commercially available frequency-
domain OCT system (Abbott, formerly St Jude Medical,
USA). Trained personnel evaluated the OCTimages of target
lesions for plaque vulnerability. Vulnerable plaques were
randomised to either PCI and subsequent stenting with a
BVS (Figure 2) or optimal medical therapy in a 1 :1 fashion.
Nomore than one lesion per patient was randomised, even if
multiple vulnerable plaques were identified. "e choice
which lesion to target was left at the discretion of the op-
erator, but preferably, the most proximal lesion was selected
and with consideration of the following hierarchy: first, the
left anterior descending artery and, second, the right cor-
onary artery in patients with a right dominant coronary
circulation or the left circumflex artery in patients with a left
dominant circulation. Patients with only FFR-positive or
only non-vulnerable lesions were excluded from the study
protocol and subjected to clinical follow-up in a registry.
2.2. OCT Analysis. OCT analysis of target lesions was per-
formed in real time during the ICA. Analysis of any addi-
tional “non-target” lesions that were captured on the OCT
pullback was performed offline using an offline review
workstation (Abbott, formerly St Jude Medical, USA).
Evaluation of the images was based on tissue characteristics
as previously described in OCT expert consensus papers
[10]. A plaque was deemed “vulnerable” if it contained two
of the following characteristics: a lipid arc (defined as a
diffusely bordered signal-poor region) of more than 90
degrees, a cap thickness (defined as a signal-rich band
overlying a lipid core) of <65 μm, and either cap rupture or
thrombus formation.
2.3. Medicinal +erapy. Patients in both groups received
pharmacologic treatment according to current guidelines.
Due to the reporting of increased stent-thrombosis of BVS
compared to metallic stents during the trial, all randomised
patients were recommended to continue dual antiplatelet
therapy (DAPT) for at least 3 years if they tolerated DAPT
without bleeding complications and were not at high
bleeding risk (e.g., prior bleeding on DAPT, coagulopathy,
or oral anticoagulant use).
2.4. Outcome Measure and Power Analysis. "e primary
outcome of this trial was a composite of all-cause mortality,
non-fatal MI, and unplanned revascularisation at 1-year
Secondary outcomes included the composite outcome at 2
and 5 years and the individual components at 1, 2, and 5
years. Based on an expected event rate of 5% in the inter-
vention group versus 13% in the OMT group, with a two-
sided alpha of 5% and a drop-out rate of 10%, 500 patients
were needed to demonstrate superiority of BVS stenting of
vulnerable plaques.
3. Results
Inclusion in the study started in March of 2016 and was
subsequently halted in March of 2017. A total of 63 patients
underwent re-ICA with FFR-measurements of non-culprit
lesions (Figure 1). In nine patients, the non-culprit lesions
were FFR-positive, and hence, subsequent revascularisation
was performed. Of the remaining 54 patients, 52 underwent
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OCT imaging of a total of 59 FFR-negative lesions, whereas 2
patients refused OCT imaging. Among the 52 that underwent
OCT imaging, a vulnerable target lesion could be identified in
41 (79%) patients. Of all 59 OCT pullbacks of FFR-negative
lesions, 44 (75%) showed a vulnerable lesion. Seven patients
were excluded due to a vessel diameter too large for BVS
implantation, resulting in a total of 34 patients who were
eventually randomised (17 BVS vs. 17 OMT). Apart from one
withdrawal of consent in the BVS group and one lost to
follow-up in the OMT group, two-year follow-up was ob-
tained of all participants that were included up to that point.
Table 2 shows patient baseline characteristics. "e mean
age of participants was 62.1± 10.4 years in BVS vs. 70.3± 5.9
years in the OMTgroup."e percentage of male participants
was 75.0% in BVS vs. 75.0% in OMT. STEMI was the initial
presentation in 43% in BVS vs. 50% in OMT. OCT char-
acteristics of the target lesions in the randomised groups
(Table 3) were as follows: the average fibrous cap thickness
was 50.0 μm± 10.3 in the BVS group vs. 50.6 μm± 10.0 in the
OMTgroup. A plaque rupture or thrombus was identified in
1 (6.25%) of the target lesions in the BVS group vs. 2 (12.5%)
in the OMT group. 100% of target lesions in both groups
contained a lipid arc of >90 degrees. "e average minimal
lumen area was 2.69± 0.99mm2 in the BVS group and
2.57± 1.07mm2 in the OMT group. In the BVS group, the
average minimal lumen area changed from 2.69± 0.99mm2
to 6.55± 1.81mm2 after stent placement. Analysis of the
OCT images beyond the angiographically targeted lesions
revealed the average presence of 0.2± 0.4 additional vul-
nerable non-target lesions and 0.7± 1.1 additional non-
vulnerable non-target lesions per OCT-pullback in the BVS
group. In the OMTgroup, an additional 0.5± 0.8 vulnerable

















































Figure 1: Study Flowchart. BVS, bioresorbable vascular scaffold, FFR, fractional flow reserve, NSTEMI, non-ST-elevation myocardial
infarction, OCT, optical coherence tomography, OMT, optimal medicinal therapy, PCI, percutaneous coronary intervention, STEMI, ST-
elevation myocardial infarction.
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During two-year follow-up, a total of 12 clinical events
were recorded, of which 4 were adjudicated as MACE
(Table 4). "e number of MACE was 3 in the BVS group and
1 in the OMT group. "e events in the BVS group were a
non-cardiac death and two non-study vessel-related MIs.
"e sole MACE in the OMTgroup was a non-cardiac death.
Apart from one elective PCI for stable angina in the OMT
group, no target lesions in any group were revascularised
during the two-year follow-up.
4. Discussion
In the PECTUS trial, patients withmyocardial infarction and
an FFR-negative OCT-based vulnerable non-culprit lesion
were randomised between an intervention with a BVS and
optimal medical therapy. Due to the low number of included
patients, no robust conclusions can be drawn with respect to
the safety or efficacy of preventive stenting of these plaques
based on this study. Nevertheless, there were some notable
results. In the 34 patients that were randomised, MACE
occurred 3 times (18.8%) in the BVS group and once (6.3%)
in the OMT group. "is would indicate that stenting of
vulnerable lesions with BVS has no evident benefit com-
pared to medical treatment or might even result in worse
outcomes. However, no case of MACE was related to a target
lesion. "e only target lesion-related event was an elective
PCI due to stable angina in the OMT group. "is is in
contrast with the AIDA trial [8], in which patients under-
going PCI were randomised between BVS and metallic
stents. In this trial, target vessel failure at 2-year follow-up
had occurred in 11.7% of patients with BVS. Additionally, no
device thrombosis was seen in the current study. "is could
suggest that BVS implantation is related to relatively low
device-related complications in these non-flow-limiting
non-complex lesions. "is is also in line with the midterm
results of BVS in STEMI-patients [11].
We observed a lower-than-expected rate of MACE
(6.3%) in the OMTgroup. In comparison, the 2-year follow-
up results of the FAME trial showed a MACE rate of 17.9%
in patients who had undergone complete FFR-guided
revascularisation [12]. A possible explanation for these
discrepancies, in addition to the limited patient population,
could be that patients in this trial were advised to continue
DAPT for up to 3 years after the index event.
Current guidelines recommend physiological measure-
ments to determine the hemodynamic significance of an-
giographic intermediate lesions, based on several large trials
[13, 14]. Despite the obvious benefit of FFR-measurements
in guiding revascularisation, long-term follow-up patients
with deferred lesions still show significant event rates."e 5-
year follow-up of the FAME trial demonstrated a 28% event
rate in patients who had been treated with FFR-guided
complete revascularisation [15]. Additionally, some studies
have suggested that FFR-guided treatment decision based on
studies in patients with stable CAD cannot simply be
adopted in ACS patients [1, 16]."erefore, besides treatment
or referral based on physiological significance, anatomical
characteristics might further improve treatment decision. In
support of this, recent multicentre non-invasive imaging
studies have clearly shown that the use of anatomical im-
aging with coronary computed tomography angiography
(CCTA) leads to a more favourable prognosis as compared
to standard of care using functional testing [17]. Addi-
tionally, a recent small single-center trial demonstrated
superiority of image-guided intervention compared with
physiology-guided intervention [18]. Although these results
have to be confirmed in larger trials, they hint at the ad-
ditional value of anatomical information in guiding coro-
nary intervention.
Table 1: Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Clinical Clinical
(i) Age ≥18 years (i) Pregnancy
(ii) Clinical presentation of STEMI or NSTEMI (ii) Severe kidney disease defined as an eGFR <30ml/min
(iii) Previous CABG
(iv) Indication for revascularization by CABG
(v) Estimated life expectancy <1 year
Angiographical Angiographical
(i) Presence of residual, intermediate CAD (diameter stenosis
of 30–90%), with the possibility of plaque vulnerability (i) Target vessel diameter <2.5mm or >4.0mm
(ii) Anatomy of lesion unsuitable for OCT catheter crossing or
imaging (aorta-ostial lesions, small diameter segment, and severe
calcifications)
(iii) Anatomy unsuitable for BVS placement (left main, bifurcation,
and side branch (>2mm) involvement)
(iv) Target lesion is
(a) In-stent restenosis
(b) Chronic total occlusion
(c) In the same vessel as treated culprit lesion
(d) In the same segment as a previously implanted stent/scaffold
BVS, bioresorbable vascular scaffold, CABG, coronary artery bypass grafting, CAD, coronary artery disease, NSTEMI, Non-ST-elevation myocardial in-
farction, OCT, optical coherence tomography, STEMI, ST-elevation myocardial infarction.
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In PECTUS, a plaque was considered eligible for ran-
domisation if it showed two characteristics of vulnerability.
Whilst all randomised target lesions contained a lipid arc of
>90 degrees, only 9% of these lesions showed a plaque rupture
or thrombus. Even though these, and other characteristics such
as neointimal vascularisation and fibrous cap inflammation,
have all been associated with plaque rupture, there is no clear
answer as to what (combination of) feature(s) is the most
hazardous. Nonetheless, the body of evidence linking plaque
morphology to MACE is growing. Following PROSPECT, the
VIVA and ATHEROREMO-IVUS studies also showed an
association between IVUS-derived characteristics of vulnera-
bility and MACE [3, 19, 20]. Moreover, this association is also
found in other imaging modalities such as near infrared
spectroscopy (NIRS) and CCTA [21, 22]. Because of the
novelty of the technique, validation studies for the ability of
OCT to detect vulnerable plaques are scarce. In the recent
CLIMA study, investigators analysed images of 1003 patients
who had undergone OCT-imaging of the proximal LAD in the
Table 2: Baseline characteristics.
BVS (n� 16) OMT (n� 16)
Age—years 62.1± 10.4 70.3± 5.9
Sex—n (%)
Male 12 (75) 12 (75)
Female 4 (25) 4 (25)
Clinical presentation—n (%)
STEMI 7 (43) 8 (50)
NSTEMI 9 (57) 8 (50)
Target vessel—n (%)
LAD 6 (37.5) 7 (43.75)
Cx 6 (37.5) 6 (37.5)
RCA 4 (25) 3 (18.75)
Average FFR 0.90± 0.07 0.90± 0.06
BVS, bioresorbable vascular scaffold, Cx, circumflex artery, LAD, left an-
terior descending artery, FFR, fractional flow reserve, NSTEMI, Non-ST-
elevation myocardial infarction, OMT, optimal medicinal therapy, RCA,












Figure 2: OCTwith angiography coregistration of a patient randomised to BVS placement. (a) Angiogram shows an intermediate stenosis
in the proximal circumflex coronary artery (white marker). (b) OCTof the stenosis reveals a vulnerable plaque (lipid arc >90° with a cap of
60 μm). (c) Angiogram shows the same lesions as in A (white marker) after BVS placement. (d). OCTshows BVS placement over vulnerable
plaque with good stent apposition.
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1 (1) BVS LAD-mid (7) 0.82 During BVSimplant
Cardiac arrest due to pulseless electrical activity
during BVS implantation, for which chest
compressions were performed for 1 minute and
atropine was given, after which return of
spontaneous circulation occurred. No mechanical
complication was seen. Postprocedural troponin
values were not elevated. Episode was attributed to a
vagal reaction.
No Yes
1 (2) BVS LAD-mid (7) 0.82 6 months
Elective PCI of proximal and distal RCA (in-stent
restenosis distal RCA) because of progressive angina.
No pre-intervention FFR was performed because
stenosis in distal RCA was 90%.
No No
2 BVS LAD-mid (7) 0.81 4 months
Cardiac arrest due to ventricular fibrillation. ICA
shows left main coronary artery occlusion, for which
PCI was performed. OCT shows good patency of
BVS in the mid LAD.
Yes No
3 BVS LAD-mid (7) 0.84 24 months Non-cardiac death due to obstruction hydrocephaluscaused by metastasized lung carcinoma. Yes No
4 BVS RCA-prox (1) 0.93 23 months Elective PCI of LAD-mid because of stable angina. No No
5 BVS LAD-mid (7) 0.86 8 days Infected hematoma of the femoral puncture site/closure device. No No
6 BVS Cx-mid (13) 0.95 15 months
STEMI with PCI of distal RCA (culprit). Additional
occlusion of a small MO2 branch."is occlusion was
not intervened upon as patient was free of
complaints after PCI of the RCA. BVS in the mid-Cx
was patent.
Yes No
7 OMT LAD-mid (7) 0.87 12 months
Non-cardiac death due to aspiration pneumonia in
patient with lymphoma and metastasized squamous
cell carcinoma.
Yes No
8 OMT Cx-mid (13) 1.00 24 months
Hospital admission with chest pain and slightly
elevated cardiac troponin levels without rise/fall.
ICA showed no obstructive coronary artery disease.
Complaints were attributed to hypertension.
No No
9 OMT Cx-prox (1) 0.83 22 months Lobectomy for newly diagnosed lung carcinoma. No No
10 OMT MO1 (12) 0.97 Same day asrandomisation Transient binocular diplopia after ICA. No No
11 OMT LAD-mid (7) 0.89 24 months
Elective PCI of the mid LAD (target segment) and
proximal RCA due to stable angina and optimisation
for esophageal cancer-related chemotherapy. No
pre-intervention FFR was performed because the
wire could not pass the mid-LAD.
No Yes
BVS, bioresorbable vascular scaffold, Cx, circumflex artery, FFR, fractional flow reserve, ICA, invasive coronary angiography, LAD, left anterior descending
artery, MACE, major adverse cardiac event, MLA, minimal lumen area, MO, obtuse marginal artery, OCT, optical coherence tomography, OMT, optimal
medicinal therapy, PCI, percutaneous coronary intervention, RCA, right coronary artery, STEMI, ST-elevation myocardial infarction.
Table 3: Target lesion OCT characteristics.
BVS (n� 16) OMT (n� 16)
Average cap thickness—μm 50.0± 10.3 50.6± 10.0
Plaque rupture or thrombus—n (%) 1 (6.25%) 2 (12.5%)
Lesions with >1 lipid quadrant—n (%) 16 (100%) 16 (100%)
Average MLA—mm2 2.69± 0.99 2.57± 1.07
Average MLA after PCI—mm2 6.55± 1.81 —
Average number of additional non-target lesions per pullback 0.9± 1.3 1.4± 0.8
(i) Vulnerable 0.2± 0.4 0.5± 0.8
(ii) Non-vulnerable 0.7± 1.1 0.9± 0.7
BVS, bioresorbable vascular scaffold, OCT, optical coherence tomography, OMT, optimal medicinal therapy, MLA, minimal lumen area, PCI, percutaneous
coronary intervention.
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context of a clinically indicated ICA."is study showed that the
combination of four morphological plaque features was an
independent predictor ofMACEwith a hazard ratio of 7.54 at 1
year [23]. In CLIMA, however, the OCT imaging was per-
formed on a fixed segment of the coronary artery tree as
opposed to a segment based on angiographic stenosis.
"erefore, the technique was evaluated more as a tool for
prognostic risk stratification instead of imaging based lesion
treatment. "e same holds true for the other intravascular
imaging studies. Data on “targeted” intravascular imaging of
angiographically defined stenoses is still lacking. Several studies
are currently trying to address this gap in knowledge. Among
them are the COMBINE study (NCT02989740) and PECTUS-
obs study (NCT03857971).
In line with the current PECTUS trial, the above-
mentioned FORZA trial also assessed OCT-guided PCI [18].
In this study, 350 patients were randomised between FFR-
guided or OCT-guided PCI of angiographically intermediate
coronary lesions. At 13-month follow-up, patients in the
OCT-guided group had significantly less MACE or signif-
icant angina compared to patients in the FFR-guided group.
However, the decision whether or not to stent a lesion in the
OCT group was based on a combination of OCT-derived
area stenosis, minimal lumen area, and the presence of
plaque rupture. "erefore, apart from plaque rupture, this
study did not take characteristics of vulnerability into ac-
count. In contrast, two other randomised studies that are
currently being conducted have a similar design to PECTUS.
"e PROSPECT-ABSORB (NCT02171065) and PREVENT
(NCT02316886) both randomise patients with residual non-
obstructive vulnerable plaques to either BVS placement or
optimal medicinal therapy although they differ in the in-
travascular imaging modality used.
5. Limitations
"e main limitation of the PECTUS trial is the low number
of included patients due to the early termination of the trial.
6. Conclusions
In conclusion, the PECTUS trial could not shed light on the
theoretical benefit of preventive stenting of non-flow-lim-
iting vulnerable lesions due to early termination of the trial.
Nonetheless, the concept of identifying and potentially
treating vulnerable plaques remains an important field for
future research given the relatively large MACE rates as
reported for this specific cohort of patients.
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